Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving Cash Flow ⢠Strong Net Cash ⢠Ongoing Losses TARS has strong liquidity and improving cash flow, but persistent losses, high costs, dilution, and demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Positive Monthly Trend ⢠Post-Peak Pullback ⢠Neutral Momentum Support Level: $77.60â$78.20; stronger support $74.00â$74.30 Resistance Level: $82.80â$83.20; major resistance $87.20â$90.80 TARS remains positive over the last month but is consolidating after a sharp pullback; hold above $77.60â$78.20 and reclaim $82.80â$83.20 for a stronger rebound outlook.
Sentiment & News
Key News Insights: ⢠Alkeus acquisition ⢠Phase 3 asset ⢠Institutional buying Tarsus's Alkeus acquisition adds promising Phase 3 Stargardt candidate gildeuretinol, broadening retinal-disease exposure amid supportive clinical, regulatory, and institutional-investor developments.
AI Summary
Tarsus has evolved from an XDEMVY launch story into a platform bet, with strong sales, 93% gross margins, and net cash positioning it for an earnings inflectionâif expense growth finally trails revenue growth. Investors should favor the shares only while XDEMVY momentum sustains and cash-flow conversion proves repeatable, as the long-dated Alkeus pipeline adds upside but also dilution and execution risk.
Description
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for ophthalmic and related conditions. Its lead candidate, TP-03, is in Phase III for blepharitis associated with Demodex infestation and for meibomian gland disease, while additional pipeline programs include treatments for rosacea, Lyme prophylaxis, and malaria reduction. The company also develops the lotilaner molecule for use across eye care, dermatology and other human medicine indications and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | TARS | Tarsus Pharmaceuticals, Inc. | Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts. | Closed | -2.5% |